Status:
RECRUITING
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
Lead Sponsor:
Fox Chase Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients
Metastatic Colorectal Cancer (CRC)
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
This is a pilot, prospective, randomized study evaluating the feasibility and acceptability of incorporating hemp-derived cannabidiol (CBD) supplementation to prevent oxaliplatin-induced peripheral ne...
Detailed Description
Patients with metastatic colorectal cancer (mCRC) scheduled to receive at least 3 months of oxaliplatin-based chemotherapy will be enrolled on this prospective, randomized, open-label pilot study. A t...
Eligibility Criteria
Inclusion
- Patients with metastatic, locally advanced unresectable colorectal cancer patients planned to receive Ox based chemotherapy in metastatic setting (at least 3 months planned).
- Subjects are allowed to have one cycle of Ox based chemotherapy before enrollment.
- ECOG PS 0-2
- No prior platinum exposure
- No evidence of ongoing neuropathy of any grade at the time of enrollment
- Patients must have marrow and organ function appropriate for systemic therapy, as per physician's discretion, but liver function should meet criteria below:
- Total Bilirubin: less than and/or equal to 1.5 X ULN
- AST(SGOT)/ALT(SGPT): less than and/or equal to 3 X ULN (5 X ULN in patients with liver metastases
- Ability to understand and willingness to sign a written informed consent and HIPAA consent document.
Exclusion
- Family history of genetic/familial neuropathy and personal history of ongoing neuropathy (any grade) or nervous system disease with the potential to affect cognition, Parkinson's disease, or multiple sclerosis.
- Routine use of recreational marijuana products (defined as \> 4 times per month) or illicit drug use per self-reported history within the last 90 days. If using medical cannabis products, it should be stopped at least 1 week prior to inclusion.
- Known underlying liver disease (Child-Pugh B or C) or baseline elevation of total bilirubin greater than and/or equal to 1.5 x upper limit of normal based on screening laboratory values.
- 1Untreated brain metastases (can increase seizure risk), or treated brain metastases on anti-seizure medications.
- Patients being treated with anti-seizure or anti-psychotic medications. Patients with a prior history of anti-seizure medication use, who have been off treatment for more than 3 months, are eligible. Use of Selective Serotonin Reuptake Inhibitors (SSRIs) is permitted.
- Concomitant treatment with strong inducers of CYP3A4 and/or strong inducers of CYP2C19.
- Underlying history of epilepsy/recurrent seizure disorder or unexplained seizure within past 6 months.
- Patients with current or lifetime diagnosis of schizophrenia spectrum disorder, psychotic disorder, bipolar disorder type I \& II, cluster B personality disorders (antisocial, borderline, narcissistic, histrionic), eating disorders, as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revised (DSM-5-TR, APA 2022)
- Recent history or clinical concern for major depression with suicidal ideation as determined by investigator assessment at baseline
- Currently taking medications known to be contraindicated with Epidiolex -FDA-approved CBD (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, teriflunomide, clobazam, lamotrigine, valproate).
- Women who are pregnant or breastfeeding, and individuals of any sex who are capable of reproduction and unwilling to use an effective form of birth control (e.g., condoms, diaphragm, birth control pills, or IUD).
- Patients may not be receiving any other investigational agents.
Key Trial Info
Start Date :
October 14 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 7 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07167446
Start Date
October 14 2025
End Date
September 7 2028
Last Update
October 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111